The use of Ginkgo biloba in Raynaud's disease: a double-blind placebo-controlled trial

Andrew H Muir, Rosalind Robb, Margaret McLaren, Fergus Daly, Jill J F Belch

    Research output: Contribution to journalArticle

    43 Citations (Scopus)

    Abstract

    Raynaud's phenomenon (RP) is a common and painful condition characterized by episodic digital ischaemia produced by emotion and cold. Treatment of RP is notoriously difficult because of the high incidence of side effects. The aim of our study was to investigate the clinical efficacy of a standardized Ginkgo biloba extract (Seredrin) in the treatment of RP in patients with no apparent, associated condition such as systemic sclerosis.
    A two-week assessment period was done during which patients were asked to record frequency, severity and duration of attacks in diaries. Subjects were then randomized independently of the study centre to receive either active or placebo treatment for 10 weeks, during which time the same data were recorded in their diaries. Patients were seen after two and four weeks of treatment and at the end of the 10-week treatment phase. Blood samples pre- and post-treatment were taken for haemorrheology.
    Only in the number of attacks per day was there a significant effect of treatment over placebo. The number of attacks per week prior to treatment with Seredrin was 13.2 ± 16.5 reducing to 5.8 ± 8.3, a reduction of 56%, whereas placebo reduced the number by only 27% (p < or = 0.00001). There were no significant differences in haamorrheology between the two groups.
    Ginkgo biloba phytosome may be effective in reducing the number of Raynaud's attacks per week in patients suffering from Raynaud's disease.
    Original languageEnglish
    Pages (from-to)265-267
    Number of pages3
    JournalVascular Medicine
    Volume7
    Issue number4
    DOIs
    Publication statusPublished - Nov 2002

    Fingerprint

    Ginkgo biloba
    Raynaud Disease
    Placebos
    Therapeutics
    Hemorheology
    Systemic Scleroderma
    Emotions
    Ischemia

    Cite this

    Muir, Andrew H ; Robb, Rosalind ; McLaren, Margaret ; Daly, Fergus ; Belch, Jill J F. / The use of Ginkgo biloba in Raynaud's disease : a double-blind placebo-controlled trial. In: Vascular Medicine. 2002 ; Vol. 7, No. 4. pp. 265-267.
    @article{d486d46d2539472da4f3cfcee30db0f2,
    title = "The use of Ginkgo biloba in Raynaud's disease: a double-blind placebo-controlled trial",
    abstract = "Raynaud's phenomenon (RP) is a common and painful condition characterized by episodic digital ischaemia produced by emotion and cold. Treatment of RP is notoriously difficult because of the high incidence of side effects. The aim of our study was to investigate the clinical efficacy of a standardized Ginkgo biloba extract (Seredrin) in the treatment of RP in patients with no apparent, associated condition such as systemic sclerosis. A two-week assessment period was done during which patients were asked to record frequency, severity and duration of attacks in diaries. Subjects were then randomized independently of the study centre to receive either active or placebo treatment for 10 weeks, during which time the same data were recorded in their diaries. Patients were seen after two and four weeks of treatment and at the end of the 10-week treatment phase. Blood samples pre- and post-treatment were taken for haemorrheology. Only in the number of attacks per day was there a significant effect of treatment over placebo. The number of attacks per week prior to treatment with Seredrin was 13.2 ± 16.5 reducing to 5.8 ± 8.3, a reduction of 56{\%}, whereas placebo reduced the number by only 27{\%} (p < or = 0.00001). There were no significant differences in haamorrheology between the two groups. Ginkgo biloba phytosome may be effective in reducing the number of Raynaud's attacks per week in patients suffering from Raynaud's disease.",
    author = "Muir, {Andrew H} and Rosalind Robb and Margaret McLaren and Fergus Daly and Belch, {Jill J F}",
    year = "2002",
    month = "11",
    doi = "10.1191/1358863x02vm455oa",
    language = "English",
    volume = "7",
    pages = "265--267",
    journal = "Vascular Medicine",
    issn = "1358-863X",
    publisher = "SAGE Publications",
    number = "4",

    }

    The use of Ginkgo biloba in Raynaud's disease : a double-blind placebo-controlled trial. / Muir, Andrew H; Robb, Rosalind; McLaren, Margaret; Daly, Fergus; Belch, Jill J F.

    In: Vascular Medicine, Vol. 7, No. 4, 11.2002, p. 265-267.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - The use of Ginkgo biloba in Raynaud's disease

    T2 - a double-blind placebo-controlled trial

    AU - Muir, Andrew H

    AU - Robb, Rosalind

    AU - McLaren, Margaret

    AU - Daly, Fergus

    AU - Belch, Jill J F

    PY - 2002/11

    Y1 - 2002/11

    N2 - Raynaud's phenomenon (RP) is a common and painful condition characterized by episodic digital ischaemia produced by emotion and cold. Treatment of RP is notoriously difficult because of the high incidence of side effects. The aim of our study was to investigate the clinical efficacy of a standardized Ginkgo biloba extract (Seredrin) in the treatment of RP in patients with no apparent, associated condition such as systemic sclerosis. A two-week assessment period was done during which patients were asked to record frequency, severity and duration of attacks in diaries. Subjects were then randomized independently of the study centre to receive either active or placebo treatment for 10 weeks, during which time the same data were recorded in their diaries. Patients were seen after two and four weeks of treatment and at the end of the 10-week treatment phase. Blood samples pre- and post-treatment were taken for haemorrheology. Only in the number of attacks per day was there a significant effect of treatment over placebo. The number of attacks per week prior to treatment with Seredrin was 13.2 ± 16.5 reducing to 5.8 ± 8.3, a reduction of 56%, whereas placebo reduced the number by only 27% (p < or = 0.00001). There were no significant differences in haamorrheology between the two groups. Ginkgo biloba phytosome may be effective in reducing the number of Raynaud's attacks per week in patients suffering from Raynaud's disease.

    AB - Raynaud's phenomenon (RP) is a common and painful condition characterized by episodic digital ischaemia produced by emotion and cold. Treatment of RP is notoriously difficult because of the high incidence of side effects. The aim of our study was to investigate the clinical efficacy of a standardized Ginkgo biloba extract (Seredrin) in the treatment of RP in patients with no apparent, associated condition such as systemic sclerosis. A two-week assessment period was done during which patients were asked to record frequency, severity and duration of attacks in diaries. Subjects were then randomized independently of the study centre to receive either active or placebo treatment for 10 weeks, during which time the same data were recorded in their diaries. Patients were seen after two and four weeks of treatment and at the end of the 10-week treatment phase. Blood samples pre- and post-treatment were taken for haemorrheology. Only in the number of attacks per day was there a significant effect of treatment over placebo. The number of attacks per week prior to treatment with Seredrin was 13.2 ± 16.5 reducing to 5.8 ± 8.3, a reduction of 56%, whereas placebo reduced the number by only 27% (p < or = 0.00001). There were no significant differences in haamorrheology between the two groups. Ginkgo biloba phytosome may be effective in reducing the number of Raynaud's attacks per week in patients suffering from Raynaud's disease.

    U2 - 10.1191/1358863x02vm455oa

    DO - 10.1191/1358863x02vm455oa

    M3 - Article

    C2 - 12710841

    VL - 7

    SP - 265

    EP - 267

    JO - Vascular Medicine

    JF - Vascular Medicine

    SN - 1358-863X

    IS - 4

    ER -